← Patent-cliff monitor small molecule FABHALTA IPTACOPAN HYDROCHLORIDE
Loss of exclusivity July 2041 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name FABHALTA Active ingredient IPTACOPAN HYDROCHLORIDE Strength EQ 200MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval December 2023 Marketing status RX
Listed patents Patent Expires Type 11951101 July 2041 use U-3895 12453726 July 2041 use U-4300 11603363 May 2041 substance, product 12384758 May 2041 use U-4161 11723901 August 2038 use U-3980 12285422 August 2038 use U-4181 10093663 July 2034 use U-3980 9682968 July 2034 substance, product
Regulatory exclusivity Code Expires ODE-524 March 2032 ODE-456 December 2030 NCE December 2028 I-963 March 2028 I-949 August 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.